OBJECTIVES: Finafloxacin is an investigational fluoroquinolone exhibiting broad-spectrum activity that is enhanced under slightly acidic conditions (pH 5.0-6.5). The impact of individual and combinations of chromosomal mutations (gyrA, parC and marR) and the plasmid-mediated fluoroquinolone resistance mechanisms QepA1, QnrA1, QnrB1, QnrS1 and AAC(6')-Ib-cr were investigated. METHODS: The MICs of finafloxacin, compared with those of ciprofloxacin, levofloxacin and moxifloxacin, were determined at pH 5.8 and 7.2. RESULTS: MICs of finafloxacin compared with other fluoroquinolones at pH 5.8 were lower by a factor of 2-256. MICs of finafloxacin were unaffected by QepA1. Moreover, finafloxacin appeared not to be a substrate for AAC(6')-Ib-cr. CONCLUSIONS: Compared with ciprofloxacin, levofloxacin and moxifloxacin, finafloxacin shows higher activity especially at pH 5.8 against Escherichia coli mutants expressing known fluoroquinolone resistance determinants alone and in combinations.
OBJECTIVES:Finafloxacin is an investigational fluoroquinolone exhibiting broad-spectrum activity that is enhanced under slightly acidic conditions (pH 5.0-6.5). The impact of individual and combinations of chromosomal mutations (gyrA, parC and marR) and the plasmid-mediated fluoroquinolone resistance mechanisms QepA1, QnrA1, QnrB1, QnrS1 and AAC(6')-Ib-cr were investigated. METHODS: The MICs of finafloxacin, compared with those of ciprofloxacin, levofloxacin and moxifloxacin, were determined at pH 5.8 and 7.2. RESULTS: MICs of finafloxacin compared with other fluoroquinolones at pH 5.8 were lower by a factor of 2-256. MICs of finafloxacin were unaffected by QepA1. Moreover, finafloxacin appeared not to be a substrate for AAC(6')-Ib-cr. CONCLUSIONS: Compared with ciprofloxacin, levofloxacin and moxifloxacin, finafloxacin shows higher activity especially at pH 5.8 against Escherichia coli mutants expressing known fluoroquinolone resistance determinants alone and in combinations.
Authors: Joanne L Platell; Rowland N Cobbold; James R Johnson; Anke Heisig; Peter Heisig; Connie Clabots; Michael A Kuskowski; Darren J Trott Journal: Antimicrob Agents Chemother Date: 2011-06-06 Impact factor: 5.191
Authors: Andreas Vente; Christine Bentley; Mark Lückermann; Paul Tambyah; Axel Dalhoff Journal: Antimicrob Agents Chemother Date: 2018-03-27 Impact factor: 5.191
Authors: F Wagenlehner; M Nowicki; C Bentley; M Lückermann; S Wohlert; C Fischer; A Vente; K Naber; A Dalhoff Journal: Antimicrob Agents Chemother Date: 2018-03-27 Impact factor: 5.191
Authors: Max Taubert; Mark Lückermann; Andreas Vente; Axel Dalhoff; Uwe Fuhr Journal: Antimicrob Agents Chemother Date: 2018-03-27 Impact factor: 5.191